Vanda Pharmaceuticals Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Q3 2026 revenues reached $69.8M (+24% YoY, +38% QoQ), driven by Fanapt ($38.8M, +24% YoY) and HETLIOZ ($21.7M, +21% YoY including ~$7M timing shift). Operating expenses fell 18% QoQ to $93.3M as Phase III work concluded. Company announced positive Phase III data for NEREUS in GLP-1-induced vomiting and HETLIOZ in Delayed Sleep-Wake Phase Disorder; BYSANTI launch expected Q4 2026; Quimilza BLA under FDA review (PDUFA: December 12, 2026). Cash declined $29.5M in Q3 to $140.5M; full-year 2026 revenue guidance raised to >$240M.
Why this rating
Strong topline growth (+24% YoY) and multiple regulatory/clinical catalysts meaningful for ~$269M-market-cap biotech; however, company still unprofitable (Q3 loss $22.6M) with cash burn (~$123M YTD); four near-term milestones (BYSANTI launch, Quimilza FDA decision, two sNDA opportunities) provide upside but execution risk remains material.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.